ArticleFolia microbiologica2025
The preventive and therapeutic role of native probiotic Lactobacillus species in controlling inflammation.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk Among Gut Microbiota, Microbial Metabolites, and Inflammatory Cytokines: Current Understanding and Future Directions.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic condition that leads to inflammation and damage to the gastrointestinal tract. Since dysregulation of the immune system is one of the triggers for IBD, taking probiotics as an immunomodulator in the gut could help control inflammation and IBD by influencing signaling pathways. The present research applied in vitro models to explore the effectiveness of our native probiotic Lactobacillus spp. in regulating MAPK and MYD88-independent inflammatory signaling pathways. We exposed HT-29 cells to Gram-negative bacteria to assess changes in inflammation-related pathways. Treatments were performed before, after, and simultaneously with a cocktail of Lactobacillus spp. (Lactiplantibacillus plantarum PR 365, Lactiplantibacillus plantarum PR 42, Lacticaseibacillus rhamnosus PR 195, Levilactobacillus brevis PR 205, Limosilactobacillus reuteri PR 100). This assessment was conducted using the quantitative real-time PCR method. According to our research, the expression of MAPK and MYD88-independent signaling pathways genes increased after exposure to Gram-negative components; however, using of our probiotic strains resulted in a significant reduction in the expression levels of MAPK genes in all treatments and phases. The expression levels of MYD88-independent genes were different following treatment with our selected Lactobacillus strain. The Lactobacillus spp. strains demonstrated anti-inflammatory effects on HT-29 cells by modulating MAPK and MYD88-independent signaling pathways. Our results indicate that these native potential probiotic strains exhibited beneficial effects in all three treatment phases. Therefore, it can be inferred that these probiotic strains, as beneficial agents, may be considered for the prevention and treatment of inflammation-related diseases such as IBD.
Indexed as
Identifiers
40903699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.